

Register now at [www.cmeuc2022.com](http://www.cmeuc2022.com)

**SUNDAY, MAY 22, 2022**

**Live CME/CE Symposium**

**6:00 PM – 6:30 PM Registration and Dinner\***

**6:30 PM – 8:00 PM CME/CE Symposium**

**Manchester Grand Hyatt San Diego  
Harbor Tower, 2nd Level, Harbor Ballroom A-C  
1 Market Place  
San Diego, California**

Earn up to 1.5 AMA PRA Category 1 Credits™  
or 1.5 Contact Hours

## NEW AND EMERGING SMALL MOLECULES

**Making A Difference in UC**

**Data and Discussions on:**

- New and emerging oral treatments for UC
- Real-world treatment strategies for individual patients
- Treatment differentiation and positioning

## FACULTY



**Edward V. Loftus, Jr, MD (Chair)**  
Professor of Medicine  
Consultant  
Division of Gastroenterology  
and Hepatology  
Department of Internal Medicine  
Mayo Clinic  
Rochester, Minnesota



**Anita Afzali MD, MPH, MHCM**  
Professor of Medicine  
Executive Vice Chair  
Department of Internal Medicine  
Associate Chief Medical Officer  
University of Cincinnati  
UC Health System  
Cincinnati, Ohio



**Remo Panaccione, MD, FRCPC**  
Professor of Medicine  
Director, Inflammatory Bowel  
Disease Group  
University of Calgary  
Calgary, Canada

### TARGET AUDIENCE

This educational activity is intended for gastroenterologists, gastroenterology physician assistants, and nurse practitioners involved in the care of patients with ulcerative colitis.

### LEARNING OBJECTIVES

- After completing this activity, participants will be better able to:
- Review the mechanisms of action of small molecules for ulcerative colitis
  - Describe features of oral small molecules for ulcerative colitis
  - Summarize clinical evidence on small molecule drugs for ulcerative colitis

### FOR PHYSICIANS

#### ACCME Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### AMA PRA Credit Designation Statement

MedEdicus designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### FOR NURSES

#### Interprofessional Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.

### DISCLOSURE POLICY

MedEdicus adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

### AMERICANS WITH DISABILITIES ACT

MedEdicus fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please contact [info@mededicus.com](mailto:info@mededicus.com) with any special needs (eg, physical and dietary) prior to the program.

### FEE INFORMATION

There is no fee for this educational activity.

This continuing medical education activity is provided by MedEdicus LLC in collaboration with Amedco.



This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.

This activity is not affiliated with Digestive Disease Week®.

\* Onsite seating is available until capacity is reached.  
Preregistered attendees will be seated first during registration.

